nach oben

Die Pathologie

Erschienen in:

21.11.2024 | Hauptreferate: Arbeitsgemeinschaften der DGP

Key considerations when implementing new diagnostic technologies in routine practice

verfasst von: Jochen Lennerz, MD PhD

Erschienen in: Die Pathologie | Sonderheft 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

The field of pathology is evolving with the integration of advanced and artificial-intelligence-powered diagnostic technologies. However, there remains a significant gap in clearly outlining the key considerations for the effective implementation of these innovations into clinical care.

Objectives

The aim of this review was to identify and address the essential aspects required to bridge the implementation gap of new diagnostic technologies in pathology.

Material and methods

This review synthesizes key elements from relevant scientific journals, organizational websites, and practical examples from pathology practice. The findings are presented as a structured framework of six key elements, supported by an infographic and illustrative cases from clinical settings.

Results

The key elements are: (1) Innovation depends more on the people driving it than on the work it demands, highlighting the importance of team collaboration and communication; (2) in-depth knowledge of the delivery system emphasizing the importance of care, IT, and administrative layers is crucial; (3) data-driven decision-making in healthcare transformation is central, with an emphasis on the process of converting real-world data (RWD) into actionable real-world evidence (RWE); (4) a proven approach for practice transformation uses a structured (utilization management strategy, UMS) framework; (5) a balanced approach toward financial sustainability, including local and systemic financial strategies, is important; and (6) ensuring safe and effective progress requires a new, collaborative definition of regulatory science, aligning innovation with regulatory oversight to support technological advancements.

Conclusion

These key aspects offer a foundational framework for integrating new technologies into healthcare. Although not exhaustive, overlooking them would miss a significant opportunity to enhance patient care.

Regulatory science is a scientific discipline that studies and develops the methods, policies, and tools required to ensure the safety, efficacy, and quality of medical products and technologies.

Arber DA et al (2022) International consensus classification of Myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200–1228. https://doi.org/10.1182/blood.2022015850CrossRefPubMedPubMedCentral

Baez-Navarro X et al (2022) Selecting patients with HER2-low breast cancer: getting out of the tangle. Eur J Cancer 175:187–192. https://doi.org/10.1016/j.ejca.2022.08.022CrossRefPubMed

Bisson T et al (2023) Anonymization of whole slide images in histopathology for research and education. Digit Health 9:20552076231171475. https://doi.org/10.1177/20552076231171475CrossRefPubMedPubMedCentral

Bluth MJ et al (2018) Molecular pathology techniques: advances in 2018. Clin Lab Med 38(2):215–236. https://doi.org/10.1016/j.cll.2018.03.004CrossRefPubMed

World Health Organization (2021) World health organization classification of tumours of the central nervous system, 5th edn. International Agency for Research on Cancer, Lyon

Bredella MA et al (2024) Administrative alignment for integrated diagnostics leads to shortened time to diagnose and service optimization. Radiology 312(1):e240335. https://doi.org/10.1148/radiol.240335CrossRefPubMed

Christopoulos P et al (2023) Real-world data for precision cancer medicine‑A European perspective. Genes Chromosomes Cancer 62(9):557–563. https://doi.org/10.1002/gcc.23135CrossRefPubMed

Dagogo-Jack I et al (2018) Clinical utility of rapid EGFR genotyping in advanced lung cancer. JCO Oncol Pract. https://doi.org/10.1200/PO.17.00299CrossRef

Dagogo-Jack I et al (2023) Integrated radiology, pathology, and pharmacy program to accelerate access to osimertinib. JCO Oncol Pract 19(9):786–792. https://doi.org/10.1200/OP.23.00031CrossRefPubMedPubMedCentral

10.

Dias-Santagata D et al (2022) Implementation and clinical adoption of precision oncology workflows across a healthcare network. Oncologist 27(11):930–939. https://doi.org/10.1093/oncolo/oyac134CrossRefPubMedPubMedCentral

11.

El Saghir NS et al (2015) Global practice and efficiency of multidisciplinary tumor boards: results of an American society of clinical oncology international survey. J Glob Oncol 1(2):57–64. https://doi.org/10.1200/JGO.2015.000158CrossRefPubMedPubMedCentral

12.

El Saghir NS et al Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book 2014:e461–6. https://doi.org/10.14694/EdBook_AM.2014.34.e461

13.

Gallas BD et al (2022) FDA fosters innovative approaches in research, resources and collaboration. Nat Mach Intell 4(2):97–98. https://doi.org/10.1038/s42256-022-00450-2CrossRefPubMedPubMedCentral

14.

Genzen JR et al (2024) The FDA’s proposed rule on laboratory-developed tests: what happens next? Lab Med 55(2):109–110. https://doi.org/10.1093/labmed/lmae001CrossRefPubMed

15.

Gilbert S (2024) The EU passes the AI Act and its implications for digital medicine are unclear. NPJ Digit Med 7(1):135. https://doi.org/10.1038/s41746-024-01116-6CrossRefPubMedPubMedCentral

16.

Gray K et al (2022) Artificial intelligence education for the health workforce: expert survey of approaches and needs. JMIR Med Educ 8(2):e35223. https://doi.org/10.2196/35223CrossRefPubMedPubMedCentral

17.

Groppi DE et al (2013) Consolidation of the north shore-LIJ health system anatomic pathology services: the challenge of subspecialization, operations, quality management, staffing, and education. Am J Clin Pathol 140(1):20–30. https://doi.org/10.1309/AJCPZHEYK8XF4FCKCrossRefPubMed

18.

Guerrero-Ulloa G et al (2023) Agile methodologies applied to the development of Internet of things (IoT)-based systems: a review. Sensors. https://doi.org/10.3390/s23020790CrossRefPubMedPubMedCentral

19.

Hammer RD et al (2020) Digital tumor board solutions have significant impact on case preparation. JCO Clin Cancer Inform 4:757–768. https://doi.org/10.1200/CCI.20.00029CrossRefPubMed

20.

Hill RG Jr. et al (2013) 4000 clicks: a productivity analysis of electronic medical records in a community hospital ED. Am J Emerg Med 31(11):1591–1594. https://doi.org/10.1016/j.ajem.2013.06.028CrossRefPubMed

21.

Hou HX et al (2024) Diagnostic test utilization management strategies as an opportunity for equitable access to molecularly informed clinical care. J Appl Lab Med 9(1):41–49. https://doi.org/10.1093/jalm/jfad079CrossRefPubMed

22.

Ivanova M et al (2024) Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch 484(1):3–14. https://doi.org/10.1007/s00428-023-03656-wCrossRefPubMed

23.

Jenkins TM et al (2024) Updates in the use of Immunohistochemical stains in breast and gynecologic pathology. Arch Pathol Lab Med 148(1):33–47. https://doi.org/10.5858/arpa.2022-0467-RACrossRefPubMed

24.

Jin Y et al (2024) Advances in spatial transcriptomics and its applications in cancer research. Mol Cancer 23(1):129. https://doi.org/10.1186/s12943-024-02040-9CrossRefPubMedPubMedCentral

25.

Johnson KB et al (2021) Electronic health records and clinician burnout: a story of three eras. J Am Med Inform Assoc 28(5):967–973. https://doi.org/10.1093/jamia/ocaa274CrossRefPubMed

26.

Kalhor K et al (2024) Mapping human tissues with highly multiplexed RNA in situ hybridization. Nat Commun 15(1):2511. https://doi.org/10.1038/s41467-024-46437-yCrossRefPubMedPubMedCentral

27.

Karargyris A et al (2023) Federated benchmarking of medical artificial intelligence with MedPerf. Nat Mach Intell 5(7):799–810. https://doi.org/10.1038/s42256-023-00652-2CrossRefPubMedPubMedCentral

28.

Kos Z et al (2020) Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 6:17. https://doi.org/10.1038/s41523-020-0156-0CrossRefPubMedPubMedCentral

29.

Lennerz JK et al (2022) A unifying force for the realization of medical AI. NPJ Digit Med 5(1):172. https://doi.org/10.1038/s41746-022-00721-7CrossRefPubMedPubMedCentral

30.

Lennerz JK et al (2021) Do not sell regulatory science short. Nat Med 27(4):573–574. https://doi.org/10.1038/s41591-021-01298-6CrossRefPubMed

31.

Lennerz JK et al (2016) Health care infrastructure for financially sustainable clinical genomics. J Mol Diagn 18(5):697–706. https://doi.org/10.1016/j.jmoldx.2016.04.003CrossRefPubMedPubMedCentral

32.

Lotter W et al (2024) Artificial intelligence in oncology: current landscape, challenges, and future directions. Cancer Discov 14(5):711–726. https://doi.org/10.1158/2159-8290.CD-23-1199CrossRefPubMedPubMedCentral

33.

Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRefPubMedPubMedCentral

34.

Marble HD et al (2020) A regulatory science initiative to harmonize and standardize digital pathology and machine learning processes to speed up clinical innovation to patients. J Pathol Inform 11:22. https://doi.org/10.4103/jpi.jpi_27_20CrossRefPubMedPubMedCentral

35.

McCafferty CL et al (2024) Integrating cellular electron microscopy with multimodal data to explore biology across space and time. Cell 187(3):563–584. https://doi.org/10.1016/j.cell.2024.01.005CrossRefPubMed

36.

Mosele MF et al (2024) Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group. Ann Oncol 35(7):588–606. https://doi.org/10.1016/j.annonc.2024.04.005CrossRefPubMed

37.

Pelter MN et al (2024) Precision medicine: hype or hope? Trends Cardiovasc Med 34(2):120–125. https://doi.org/10.1016/j.tcm.2022.11.001CrossRefPubMed

38.

Prelaj A et al (2024) Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol 35(1):29–65. https://doi.org/10.1016/j.annonc.2023.10.125CrossRefPubMed

39.

Raghavan D et al (2021) Levine cancer institute financial toxicity tumor board: a potential solution to an emerging problem. JCO Oncol Pract 17(10):e1433–e1439. https://doi.org/10.1200/OP.21.00124CrossRefPubMedPubMedCentral

40.

Smith L et al (2024) The US FDA’s proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing. Pract Lab Med 40:e407. https://doi.org/10.1016/j.plabm.2024.e00407CrossRefPubMedPubMedCentral

41.

Swillens JEM et al (2023) Pathologists’ first opinions on barriers and facilitators of computational pathology adoption in oncological pathology: an international study. Oncogene 42(38):2816–2827. https://doi.org/10.1038/s41388-023-02797-1CrossRefPubMedPubMedCentral

42.

- (2024) There are holes in Europe’s AI Act—and researchers can help to fill them. Nature 625(7994):216. https://doi.org/10.1038/d41586-024-00029-4CrossRefPubMed

43.

Thierauf J et al (2019) Clinically integrated molecular diagnostics in adenoid cystic carcinoma. Oncologist 24(10):1356–1367. https://doi.org/10.1634/theoncologist.2018-0515CrossRefPubMedPubMedCentral

44.

Tucci F et al (2024) The digital revolution in pathology: towards a smarter approach to research and treatment. Tumori 110(4):241–251. https://doi.org/10.1177/03008916241231035CrossRefPubMed

45.

Vogeser M et al (2022) Partial postponement of the application of the in vitro diagnostic medical devices regulation in the European Union. Clin Chem 68(6):856–857. https://doi.org/10.1093/clinchem/hvac048CrossRefPubMed

46.

- (2023) Why the UK-led global AI summit is missing the point. Nature 623(7985):7. https://doi.org/10.1038/d41586-023-03333-7CrossRefPubMed

47.

Wilm F et al Mind the gap: scanner-induced domain shifts pose challenges for representation learning in histopathology. In: 2023 IEEE 20th international symposium on biomedical imaging (ISBI)2023, pp 1–5

48.

Zhu H et al (2020) PCR past, present and future. Biotechniques 69(4):317–325. https://doi.org/10.2144/btn-2020-0057CrossRefPubMed

49.

Illumina (2024) https://www.illumina.com/company/news-center/multimedia-images.html. Accessed 14 Aug 2024

50.

Massachusetts General Hospital (2024) https://www.massgeneral.org/pathology/about. Accessed 12 Aug 2024

Titel: Key considerations when implementing new diagnostic technologies in routine practice
verfasst von: Jochen Lennerz, MD PhD
Publikationsdatum: 21.11.2024
Verlag: Springer Medizin
Erschienen in: Die Pathologie / Ausgabe Sonderheft 1/2024
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-024-01396-5

Bericht der Arbeitsgemeinschaft Geschichte und Ethik der Pathologie

Pathologie
Verbandsmitteilung

Neuroendokrine Karzinome des Gastrointestinaltrakts

Neuroendokrine Tumoren
Verbandsmitteilung

Bericht der Arbeitsgemeinschaft Uropathologie der Deutschen Gesellschaft für Pathologie

Pathologie
Verbandsmitteilung

Bericht der Arbeitsgemeinschaft Gastroenteropathologie der Deutschen Gesellschaft für Pathologie

Pathologie
Verbandsmitteilung

Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms

Hauptreferate: Arbeitsgemeinschaften der DGP

Wissenschaft und Teamgeist begeistern Teilnehmer*innen bei der 107. Jahrestagung der DGP in München

Pathologie
Editorial

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

20.01.2025
Koronare Herzerkrankung
Nachrichten

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

20.01.2025
Chronische Herzinsuffizienz
Nachrichten

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

17.01.2025
Dekubitus
Nachrichten

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen